J
Jon Lindstrom
Researcher at University of Pennsylvania
Publications - 442
Citations - 50369
Jon Lindstrom is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Acetylcholine receptor & Nicotinic agonist. The author has an hindex of 108, co-authored 441 publications receiving 48999 citations. Previous affiliations of Jon Lindstrom include University of California, San Diego & University of California, Riverside.
Papers
More filters
Journal ArticleDOI
Study of frog sartorius muscle acetylcholine receptor using the irreversible inhibitor TDF.
TL;DR: It is shown that specific reversible binding of the trimethylammonium group of TDF to the receptor plays little or no role in the irreversible reaction of T DF with the receptor, which accounts for the extremely low specificity of its reaction with the receptors.
Book ChapterDOI
Affinity purification of nicotinic acetylcholine receptor from rat brain
TL;DR: In this report, the immuno-affinity-purified nAChR accounts for more than 90% of the high affinity H-nicotine binding sites in a detergent extract of rat brain.
Journal Article
Acetylcholine receptors and myasthenia gravis: the effect of antibodies to eel acetylcholine receptors on eel electric organ cells.
TL;DR: Although antibodies could bind to most of the receptors, resulting in substantial inhibition of the depolarizing response, binding of 125-I-alpha-bungarotoxin to the cells was only slightly inhibited, suggesting that the antibodies inhibited receptor activity primarily by interfering with the ionophore of the receptor or its regulation by the acetylcholine binding site.
Journal ArticleDOI
Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption.
Jingyi Wang,Angelo Blasio,Holly L. Chapman,Christelle Doebelin,Victor Liaw,Alexander Kuryatov,Simone M. Giovanetti,Jon Lindstrom,Li Lin,Michael D. Cameron,Theodore M. Kamenecka,Matthew B. Pomrenze,Robert O. Messing +12 more
TL;DR: It is concluded that compounds targeting the (α4)3(β2)2 subtype of nAChRs can reduce alcohol consumption, and when administered in combination with varenicline, may allow use of lower varennicline doses to decrease varencline side effects.